Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 60Active not recruiting 8Terminated 6Withdrawn 5Unknown 3Recruiting 3No longer available 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 4Plasma cell 1

Conditions

Prostatic Neoplasms 4Prostatic Neoplasms, Castration-Resistant 1Multiple Myeloma 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × radium Ra 223 dichloride × Clear all
NCT05771896 2023-09-14

CARE

GenesisCare USA

Phase 3 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT03325127 2018-10-31

Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study

Bayer

Withdrawn
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT02656563 2016-10-14

RAND

Canadian Urology Research Consortium

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT02605356 2016-10-07

Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma

Bayer

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma

NCT02396368 2015-11-20

Radium-223

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡